Investors

Strong period of growth

OptiBiotix Health plc (AIM: OPTI; OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces its unaudited results for the six months ended 30 June 2025.

Highlights

• Significantly increased sales with revenue up 102% to £557K (H1 2024: £276K)
• Gross profit margin increased to 54% (H1 2024: 40%)
• Gross profit up 173% to £303K (H1 2024: £111K)
• Administrative costs (including selling, R&D and patent costs and excluding shared based payments, depreciation, and amortisation) remain relatively stable at £1.15m (H1 2024: £1.07m)
• Strong cash balance of £1.3m (H1 2024: £1.3m)
• First order received of six metric tonnes from Brenntag, the Company's new Australian distributor
• Launch of products in the USA with two new partners (NHT Global and Nouri)
• The number of e-commerce customers up by 38% to 5,095 customers (H1 2024: 3,702 customers) due to a 57.7% increase in Amazon orders to 4,159 (H1 2024: 2,638)
• E-commerce Amazon sales up 87.6% to £93,767 (H1 2024: £49,995)
• Appointed new trading partner in China with a focus on TMALL sales
• Growing list of new customers in Asia and the USA

Post period

• Launch of SlimBiome® in Hydroxycut, which markets itself as the No. 1 selling weight loss supplement brand in the United States of America ("USA")
• Signing of a distribution agreement with a well-known direct selling weight management company with a first order expected in H2 and product launch in H1 2026
• First order received from a new partner in Taiwan, Meelung Trading
• Discovery of a new enzyme for SweetBiotix which has substantially higher yields which will significantly improve manufacturing costs. The same enzyme can generate multiple SweetBiotix products with a wide sweetness range when compared to sucrose

The Company delivered strong financial performance in H1 2025, with sales more than doubling compared to H1 2024, supported by improved margins. Equally important is that we are now seeing a growing contribution from our India and USA businesses. We anticipate continued momentum in sales growth with the full year effect of 2024 launches, new and existing partners launching new products in USA and Asia, e-commerce continuing its growth trajectory with launch of products on Amazon India, and annual license revenues from SweetBiotix occurring in H2 2025.

The Company should see the effect of reductions in PR, broker, and staff costs in H2 2025 and a recently negotiated 30% reduction in IP costs. It continues to work on further margin improvements by negotiating reductions in the cost of goods from volume discounts, and supplying Asia from India, which has lower manufacturing costs.

Stephen O'Hara, CEO of OptiBiotix Health plc said: "The strong growth in 2024 has continued with increased momentum into H1 2025 and sales growth across all areas of business. Equally important are the steps we have taken to reduce costs and improve margins whilst continuing to grow sales.

"The Company has increasing sales and margins, regulatory approvals and health claims approved in all major territories, and a network of more reliable global manufacturing and distribution partners. This gives the Company a broad base on which to deliver future revenue growth with the aim of achieving profitability across all parts of the business and the Group generating positive cashflow."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact: OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD and Broker)		Tel: 020 7213 0880
Liam Murray / Ludovico Lazzaretti / James Western

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI; OTCQB: OPTBF), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.